Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been referred with a condition called CTED or CTEPH — these are lung conditions caused by old blood clots that have not fully cleared, which can make the heart and lungs work harder and cause breathing difficulties.
- People whose diagnosis is supported by at least one of the following: specific measurements of blood pressure in the lungs (taken during a heart procedure called a right heart catheterization) that are above certain levels, OR imaging scans (such as a VQ scan, CT scan, MRI, or pulmonary angiogram) showing signs of old blood clot disease in the lungs.
- People who have difficulty exercising due to this chronic blood clot disease in the lungs, even if their resting lung blood pressure measurements are not elevated.
- People who have been taking blood-thinning medication (anticoagulation) for at least 3 months before their diagnosis was confirmed.
- People aged 18 years or older.
Who may not be able to join:
- People whose high lung blood pressure is caused by something other than chronic blood clots (the trial is specifically for a type known as WHO Group 4 pulmonary hypertension).
- People who do not wish to take part in clinical research or are not willing to receive the treatment being studied.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Miles Conrad, MD, University of California, San Francisco
Phone: (415) 353-1300
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Total number of patients who survive; Changes in exercise tolerance; Changes in supplemental oxygen use severity; Changes in New York Heart Association (NYHA) functional class; European Quality of Life Five Dimension (EQ-5D) - Scale Score; Changes in patients' emPHasis-10 scores; Number of patients undergoing lung transplantation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.